Silicon AngleR. Danes Is investor belt-tightening brought on by COVID-19 the bitter medicine needed to bring sanity to the artificial intelligence funding bubble, flush out fakes, and shift venture capitalists’ attention to the most deserving companies? In...
BBCJane Wakefield, Technology Reporter Normally, just getting them all to work together would take “a year of paperwork”, said Scipher’s chief executive Alif Saleh. But a series of Zoom calls with a “group of people with a unprecedented...
Optum Ventures is among companies investing $25 million, betting on the company’s ability to show for which patients Humira doesn’t work. Healthcare Finance NewsSusan Morse, Managing Editor Humira is the top-selling prescription drug by revenue....
Appoints Slava Akmaev, Ph.D., as Chief Technology Officer WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed most effective therapy, today announces the addition of Slava...
Investment to Accelerate Molecular Diagnostic Product Selection, Development and Accessibility WALTHAM (February 19, 2020) — Scipher Medicine, a developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy, announced...
Scipher Medicine believes patients with autoimmune diseases deserve a simple answer to their treatment plan using scientifically backed data. By applying network medicine to its platform, we are developing diagnostic tests to identify patients who will not respond to...
Technology to significantly improve outcomes for autoimmune disease patients by ensuring optimal therapy is prescribed from day one WALTHAM, MA – December 19, 2019—Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed...
Scipher aims to improve drug response predictions by incorporating protein interaction networks in its gene expression analysis algorithms. To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction map into its...
The Precision Medicine Era PharmaVoice outlines why now is a new era of healthcare driven by precision medicine and how we got here, including the new trends in research to how we are moving these advancements out of research onto the market. Multiple leaders in...
Shifting Precision Medicine from Oncology to Autoimmune Diseases The Bio Report featured a podcast about precision medicine in autoimmune diseases and spoke with Alif Saleh, CEO of Scipher, to learn more about how we use gene expression data, instead of DNA, to...
Feixiong Cheng1,2,3,4,5, István A. Kovács1,2 & Albert-László Barabási1,2,6,7 Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating multiple complex diseases. Yet, our ability to identify and...
Boston Business Journal highlights local companies advancing healthcare using AI Artificial intelligence is changing healthcare from how we diagnose diseases, model drug development, and predict response to therapies. The Boston Business Journal names Scipher Medicine...
Scipher Medicine was featured in Technology Networks to discuss the power of RNA “Ineffective drugs have a profound impact on patients. First of all, the patient could be taking a medication that not only doesn’t make them feel better, but could also...
Published by GenomeWeb Scipher Medicine of Boston is hoping to develop molecular signatures that can predict a patient’s response to autoimmune disease drugs, pushing precision medicine into areas other than oncology. The company, which was founded in 2014 by...
Scipher Medicine Reports Positive Results for Prism, a Drug Response Test That Can Save the Health Insurance Industry $20 Billion by Avoiding Paying for Ineffective Therapies The blood test ensures patients with autoimmune diseases are prescribed the most effective...
